Luminex inks microRNA diagnostics agreement
This article was originally published in Clinica
Executive Summary
Luminex has licensed from the Massachusetts Institute of Technology (MIT) rights to develop and commercialise assays and related products based on microRNA, a recently discovered form of RNA that could have significant impact on the clinical diagnosis of cancer.